A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

by lowes1 on October 8, 2013

Condition:   Solid Tumors
Interventions:   Drug: Docetaxel;   Drug: vantictumab
Sponsors:   OncoMed Pharmaceuticals, Inc.;   OncoMed Pharmaceuticals, Inc.
Recruiting – verified October 2013

View full post on ClinicalTrials.gov: “Lung Neoplasms” | updated in the last 30 days

Leave a Comment

Previous post:

Next post: